Mutation of the von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system

Journal of Pathology

Volumn 179, Issue 2, 1996, Pages 151-156

  Oberstraß, Jürgen ^a   Reifenberger, Guido ^a,b   Reifenberger, Julia ^a,b   Wechsler, Wolfgang ^a   Collins, V Peter ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

capillary haemangioblastoma; gene mutation; VHL; von Hippel Lindau disease

Indexed keywords

AMINO ACID SUBSTITUTION; ARTICLE; BASE PAIRING; CANCER SCREENING; CAPILLARY HEMANGIOMA; CENTRAL NERVOUS SYSTEM TUMOR; DNA SEQUENCE; FRAMESHIFT MUTATION; GENE MUTATION; HEMANGIOBLASTOMA; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

ADOLESCENT; ADULT; AGED; BASE SEQUENCE; CEREBELLAR NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; HEMANGIOBLASTOMA; HIPPEL-LINDAU DISEASE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEIC ACID HETERODUPLEXES; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE ANALYSIS, DNA; SPINAL NEOPLASMS;

EID: 0029893946     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199606)179:2<151::AID-PATH556>3.0.CO;2-0     Document Type: Article

References (37)

1. Burger PC, Scheithauer BW. Tumours of the central nervous system. In: Atlas of Tumour Pathology, Third Series. Fascicle 10. Washington, DC: Armed Forces Institute of Pathology, 1994; 239-243.
2. Russell D, Rubinstein LJ. Pathology of Tumours of the Nervous System. 5th edn. London: Edward Arnold, 1989; 639-657.
3. Neumann HP, Eggert HR, Weigel K, Friedburg H, Wiestler OD, Schollmeyer P. Hemangioblastoma of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome. J Neurosurg 1989; 70: 24-30.
4. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumour suppressor gene. Science 1993; 260: 1317-1320.
5. Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994; 3: 2169-2173.
6. Shuin T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumour suppressor gene in primary human renal cell carcinomas. Cancer Res 1994; 54: 2852-2855.
7. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet 1994; 7: 85-89.
8. Kanno H, Kondo K, Ito S, et al. Somatic mutations of the von Hippel-Lindau tumour suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994; 54: 4845-4847.
9. Kleihues P, Burger PC, Scheithauer B. Histological Typing of Tumours of the Central Nervous System. Berlin: Springer-Verlag, 1993.
10. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991; 51: 2164-2172.
11. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-2739.
12. Sekido Y, Bader S, Latif F, et al. Molecular analysis of the von Hippel-Lindau disease tumour suppressor gene in human lung cancer cell lines. Oncogene 1994; 9: 1599-1604.
13. Rosenbauer V, Riesner D. Temperature-gradient gel electrophoresis-thermodynamic analysis of nucleic acids and proteins in purified form and in cellular extracts. Biophys Chem 1987; 26: 235-246.
14. Hansen MF, Cavenee WK. Tumour suppressors: recessive mutations that lead to cancer. Cell 1988; 53: 172-173.
15. Weinberg RA. Tumour suppressor genes. Science 1991; 254: 1138-1146.
16. Chung R, Whaley J, Kley N, et al. TP53 gene mutations and 17p deletions in human astrocytomas. Genes Chrom Cancer 1991; 3: 323-331.
17. von Deimling A, Eibl RH, Ohagaki H, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992; 53: 2987-2990.
18. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation and loss of heterozygosity on chromosome 17 and 10 during human astrocytoma progression. Cancer Res 1992; 52: 674-679.
19. Frankel R, Bayonu W, Koslow M, Newcomb EW. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 1992; 52: 1427-1433.
20. He J, Allen JR, Collins VP, et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994; 54: 5804-5807.
21. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p161MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54: 6321-6324.
22. Moulton T, Samara G, Chung WY, et al. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 1995; 146: 613-619.
23. Irving RM, Moffat DA, Hardy DG, Barton DE, Xuerreb JH, Maher ER. Somatic NF2 gene mutations in familial and non-familial vestibular Schwannoma. Hum Mol Genet 1994; 3: 347-350.
24. Twist EC, Ruttlege MH, Rousseau M, et al. The neurofibromatosis type 2 gene is inactivated in Schwannomas. Hum Mol Genet 1994; 3: 147-151.
25. Ruttlege MH, Sarrazin J, Rangaratnam S, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nature Genet 1994; 6: 180-184.
26. Maher ER, Yates JR, Harris R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 77: 1151-1163.
27. Herman JG, Latif F, Weng Y, et al. Silencing the VHL tumour-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-9704.
28. Morii K, Tanaka R, Washiyama K, Kumanishi T, Kuwano R. Expression of vascular endothelial growth factor in capillary hemangioblastoma. Biochem Biophys Res Commun 1993; 194: 749-755.
29. Wizigmann-Voos S, Breier G, Risau W, Plate KH. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 1995; 55: 1358-1364.
30. Reifenberger G, Reifenberger J, Bilzer T, Wechsler W, Collins VP. Coexpression of transforming growth factor alpha and epidermal growth factor receptor in capillary hemangioblastomas of the central nervous system. Am J Pathol (in press).
31. Tory K, Brauch H, Linehan M, et al. Specific genetic changes in tumours associated with von Hippel-Lindau disease. J Natl Cancer Inst 1989; 81: 1097-1101.
32. Crossey PA, Foster K, Richards FM, et al. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet 1994; 93: 53-58.
33. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
34. Maher ER, Yates JR, Ferguson-Smith MA. Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar hemangioblastoma and renal cell carcinoma. J Med Genet 1990; 27: 311-414.
35. Crossey PA, Richards FM, Foster K, et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994; 3: 1303-1308.
36. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumour suppressor gene: correlations with phenotype. Hum Mutat 1995; 5: 66-75.
37. Neumann HPH, Lips CJM, Hsia YE, Zbar B. Von Hippel-Lindau syndrome. Brain Pathol 1995; 5: 181-193.